Sign in →

Test ID: CTXP Cerebrotendinous Xanthomatosis, Plasma


Advisory Information


For assessment of bile acid malabsorption in patients with irritable bowel syndrome-diarrhea, order 7AC4 / 7AC4, Bile Acid Synthesis, Serum.



Specimen Required


Collection Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Green top (sodium heparin, lithium heparin) or yellow top (ACD B)

Submission Container/Tube: Plastic vial

Specimen Volume: 0.3 mL

Collection Instructions:

1. Centrifuge at 4° C, if possible

2. Aliquot plasma being careful to ensure no buffy coat is transferred with the plasma then freeze.


Forms

If not ordering electronically, complete, print, and send an Inborn Errors of Metabolism Test Request (T798) with the specimen.

Useful For

Evaluating patients with a clinical suspicion of cerebrotendinous xanthomatosis (CTX)

 

Monitoring of individuals with CTX on chenodeoxycholic acid (CDCA) therapy

 

This test is not useful for the identification of carriers

 

This test is not useful for the evaluation of bile acid malabsorption

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

Cerebrotendinous Xanthomatosis, P

Specimen Type

Plasma

Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time
Plasma Frozen 65 days

Clinical Information

Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive disorder of bile acid synthesis resulting from the deficiency of the mitochondrial enzyme, sterol 27-hydrolase. Sterol 27-hydrolase facilitates the first step of sterol degradation in the formation of bile acids; consequently patients with CTX will experience increased storage of the sterol, cholestenol, and ketosterol bile acid precursors (7-alpha-hydroxy-4-cholesten-3-one [7a-C4] and 7-alpha,12-alpha–dihydroxycholest-4-en-3-one [7a12aC4]) in multiple tissues throughout the body with a resulting deficiency of the bile acid, chenodeoxycholic acid (CDCA). CTX is caused by mutations in the CYP27A1 gene.

 

Patients with CTX can present with a constellation of findings including infantile onset diarrhea, childhood onset cataracts, development of tendon/cerebral xanthomas in adolescence and early adulthood, early onset osteoporosis, as well as a broad array of neuropsychological manifestations (such as intellectual disability, dementia, psychiatric symptoms, ataxia, pyramidal signs, dystonia, muscle weakness). Patients may occasionally present with cholestatic liver disease (jaundice, poor growth, hepatosplenomegaly). Intrafamilial variability exists and some heterozygous carriers may experience a higher incidence of cardiac disorders or gallstones. Treatment with CDCA normalizes bile acid synthesis and suppresses cholestenol biosynthesis, with improvement of clinical symptoms and arrest of disease progression. Supplementation with beta-hydroxy beta-methylglutaryl-CoA (HMG-CoA) inhibitors and coenzyme Q (CoQ10) has been proposed. The availability of effective therapy makes early diagnosis and treatment of patients with CTX essential.

 

The estimated incidence of CTX is 1 in 50,000 individuals of Northern European ancestry and as high as 1 in 440 in the Druze population of Israel.

 

The diagnostic evaluation of patients with suspected CTX may reveal abnormalities on brain magnetic resonance imaging (such as cerebellar atrophy, decrease in volume of grey and white matter, and abnormal white matter signal) in addition to the biochemical and clinical abnormalities. The diagnosis of CTX can be confirmed by molecular genetic analysis of the CYP27A1 gene (included in: MSNP / Metabolic/Syndromic Neuropathy Panel by Next-Generation Sequencing [NGS]).

Reference Values

7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE (7a-C4)

Cutoff: ≤0.300 nmol/mL

 

7-ALPHA,12 ALPHA–DIHYDROXYCHOLEST-4-en-3-ONE (7a12aC4)

Cutoff: ≤0.100 nmol/mL

Interpretation

An elevation of 7-alpha-hydroxy-4-cholesten-3-one (7a-C4) and 7-alpha,12-alpha-dihydroxycholest-4-en-3-one (7a12aC4) is strongly suggestive of cerebrotendinous xanthomatosis.

Clinical Reference

1. Mignarri A, Magni A, Del Puppo M, et al: Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis. J Inherit Metab Dis 2016;39:75-83

2. Nie S, Chen G, Cao X, Zhang Y: Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2014;9:179

3. DeBarber AE, Luo J, Star-Weinstock M, et al: A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns. J Lipid Res 2014;55:146-154

4. Federico A, Dotti MT, Gallus GN. Cerebrotendinous Xanthomatosis. In GeneReviews Edited by RA Pagon, MP Adam, HH Ardinger, et al. University of Washington, Seattle. 1993-2019. 2003 Jul 16. Accessed May 2019. Available at www.ncbi.nlm.nih.gov/books/NBK1409/

Day(s) and Time(s) Performed

Tuesday and Thursday; 8 a.m.

Analytic Time

2 days (not reported on Saturday or Sunday)

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

82542

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CTXP Cerebrotendinous Xanthomatosis, P 92746-7

 

Result ID Test Result Name Result LOINC Value
BA4379 Interpretation (CTXP) 59462-2
BA4376 7a-hydroxy-4-cholesten-3-one 92761-6
BA4377 7a,12a-dihydroxycholest-4-en-3-one 92758-2
BA4378 Reviewed By 18771-6
Mayo Clinic Laboratories | Genetics and Pharmacogenomics Catalog Additional Information:

mml-biochemical